Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC?

Yulong Zheng1, Nong Xu1, Jianying Zhou2

  • 1Department of Medical Oncology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China.

The Lancet. Oncology
|October 2, 2013
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos